Zevra Therapeutics, Inc. ZVRA Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue, net by Product | ||||||
| MIPLYFFA | $94.9M+285% | $87.4M+765% | $63.53M— | $43.65M— | $24.68M— | |
| OLPRUVA | $1M+400% | $800K+300% | $600K+500% | $500K+400% | $200K+100% | |
| Segment long-lived assets by Geography | ||||||
| Europe | $1.5M— | $1.6M— | $1.7M— | —— | —— | |
| UNITED STATES | $8.2M— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Zevra Therapeutics, Inc. break its business down?
- Zevra Therapeutics, Inc. (ZVRA) reports revenue, net by product across 2 parts — MIPLYFFA and OLPRUVA. Each is extracted from the segment footnotes and tracked over time.
- Where does Zevra Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Zevra Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
